110916 Iran US IsraeliPerspII

download 110916 Iran US IsraeliPerspII

of 102

Transcript of 110916 Iran US IsraeliPerspII

  • 7/31/2019 110916 Iran US IsraeliPerspII

    1/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    2/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    3/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    4/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    5/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    6/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    7/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    8/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    9/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    10/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    11/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    12/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    13/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    14/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    15/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    16/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    17/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    18/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    19/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    20/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    21/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    22/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    23/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    24/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    25/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    26/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    27/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    28/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    29/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    30/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    31/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    32/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    33/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    34/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    35/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    36/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    37/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    38/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    39/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    40/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    41/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    42/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    43/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    44/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    45/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    46/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    47/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    48/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    49/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    50/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    51/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    52/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    53/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    54/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    55/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    56/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    57/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    58/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    59/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    60/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    61/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    62/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    63/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    64/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    65/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    66/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    67/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    68/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    69/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    70/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    71/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    72/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    73/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    74/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    75/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    76/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    77/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    78/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    79/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    80/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    81/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    82/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    83/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    84/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    85/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    86/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    87/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    88/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    89/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    90/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    91/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    92/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    93/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    94/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    95/102

    Chemical & Biological Options

  • 7/31/2019 110916 Iran US IsraeliPerspII

    96/102

    Q 50 for Some Types of BW -

  • 7/31/2019 110916 Iran US IsraeliPerspII

    97/102

    Open-Air Deployment Plague (liquid): 3.5-4.5 liter/sq.km Tularemia (dry): 3.0-4.0 kg/sq.km Anthrax (dry, old version): 15-20 kg/sq.km Anthrax (dry, new version): 4.5-5.0 kg/sq.km

    Anthrax (liquid): 5.0-5.5 liter/sq.km Brucellosis (dry): 3.5-4.5 kg/sq.km Glanders/Melioidosis (liquid): 4.5-5.5 liter/sq.km

    Smallpox (liquid): 3.5-4.0 liter/sq.km Marburg (dry): less than 1.0 kg/sq.km

    New Types of Biological Weapons

  • 7/31/2019 110916 Iran US IsraeliPerspII

    98/102

    Binary biological weapons that use two safe to handle elements that can be assembled before use.This could be a virus and helper virus like Hepatitis D or a bacterial virulence plasmid like E. coli,plague, Anthrax, and dysentery.

    Designer genes and life forms, which could include synthetic genes and gene networks, syntheticviruses, and synthetic organisms. These weapons include DNA shuffling, synthetic forms of the flu which killed more people in 1918 than died in all of World War I and which still kills about 30,000Americans a year and synthetic microorganisms.

    "Gene therapy" weapons that use transforming viruses or similar DNA vectors carrying Trojanhorse genes (retrovirus, adenovirus, poxvirus, HSV-1). Such weapons can produce single individual(somatic cell) or inheritable (germline) changes. It can also remove immunities and wound healingcapabilities.

    Stealth viruses can be transforming or conditionally inducible. They exploit the fact that humansnormally carry a substantial viral load, and examples are the herpes virus, cytomegalovirus,Epstein-Barr, and SV40 contamination which are normally dormant or limited in infect but can betransformed into far more lethal diseases. They can be introduced over years and then used toblackmail a population.

    Host-swapping diseases: Viral parasites normally have narrow host ranges and develop anevolutionary equilibrium with their hosts. Disruption of this equilibrium normally produces noresults, but it can be extremely lethal. Natural examples include AIDS, Hantavirus, Marburg, andEbola. Tailoring the disruption for attack purposes can produce weapons that are extremely lethaland for which there is no treatment. A tailored disease like AIDS could combine serious initiallethality with crippling long-term effects lasting decades.

    Designer diseases involve using molecular biology to create the disease first and then constructing apathogen to produce it. It could eliminate immunity, target normally dormant genes, or instructcells to commit suicide. Apoptosis is programmed cell death, and specific apoptosis can be used tokill any mix of cells.

  • 7/31/2019 110916 Iran US IsraeliPerspII

    99/102

    Soviet RBK-type Cluster Bomb for CBR Weapons

    Source: Ken Alibeck

  • 7/31/2019 110916 Iran US IsraeliPerspII

    100/102

  • 7/31/2019 110916 Iran US IsraeliPerspII

    101/102

    State Actor Covert Bioterrorism, Suitcase Nuclear

    Bypasses defenses.

    Plausible deniability?

    Exploits special vulnerability of one bomb states.

    Psychological and political impacts as important as direct killing

    effects. False flag and proxy options clear.

    Buying time may limit risk of retaliation.

    Allows to exploit slow kill nature of biological strikes. Achieve line source effects

    Covert forces in place can restrike or escalate.

    Target potentially faces major weakening of conventionalcapabilities without ability to counter-escalate.

    Possible Terrorist/Covert/Irregular

  • 7/31/2019 110916 Iran US IsraeliPerspII

    102/102

    Deployment of Biological Weapons Use of infected vectors (mosquitoes, fleas, lice, etc.)

    Contamination of food and water supplies

    Contamination of various articles (letters, books, surfaces,etc.)

    Use of different aerosolizing devices and approaches tocontaminate inner spaces of various buildings (line andpoint sources)

    Use of different aerosolizing devices and approaches foropen-air dissemination (line and point sources)

    Inner- and outer-space explosive dissemination includingsuicide bombers

    T i t/S b t g th d f i f ti g d li t k